ArticleMelanoma research2017
Risk factors for development of melanoma brain metastasis and disease progression: a single-center retrospective analysis.
Article in Melanoma research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 34 citations in OpenAlex.
- A Novel Nomogram and Risk Classification System Predicting the Cancer-Specific Mortality of Patients with Initially Diagnosed Metastatic Cutaneous Melanoma.Annals of surgical oncology · 2021Trial
- Atopy Improves Survival and Decreases Risk of Brain Metastasis in Cutaneous Melanoma.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2025Article
- The Effect of Concomitant Immunotherapy and Stereotactic Radiotherapy, and of Location on Survival in Patients With Brain Metastases From Melanoma.Cancer medicine · 2025Article
- Immune checkpoint inhibitor therapy is associated with a decreased risk of developing melanoma brain metastases.BJC reports · 2025Article
- Predictive and Prognostic Factors in Melanoma Central Nervous System Metastases-A Cohort Study.Cancers · 2024Article
- Prevention of Brain Metastases: A New Frontier.Cancers · 2024Review
- Prognostic Value of BaselineCancers · 2023Article
- Differential Distribution of Brain Metastases from Non-Small Cell Lung Cancer Based on Mutation Status.Brain sciences · 2023Article
- Burden and Risk Factors of Brain Metastases in Melanoma: A Systematic Literature Review.Cancers · 2022Review
- Melanoma Brain Metastases: An Update on the Use of Immune Checkpoint Inhibitors and Molecularly Targeted Agents.American journal of clinical dermatology · 2022Review
- Mefloquine induces ER stress and apoptosis in BRAFi-resistant A375-BRAFMolecular carcinogenesis · 2022Article
- Brain metastases: the role of clinical imaging.The British journal of radiology · 2022Review
- Analysis of Demographics and Outcomes of Surgical Resection in the Central Nervous System of Patients With Metastatic Melanoma.World journal of oncology · 2021Article
- Incidence and characteristics of metastatic intracranial lesions in stage III and IV melanoma: a single institute retrospective analysis.Journal of neuro-oncology · 2021Article
- Brain Tumor Microenvironment and Angiogenesis in Melanoma Brain Metastases.Frontiers in oncology · 2020Article
- Predictive value of a nomogram for melanomas with brain metastases at initial diagnosis.Cancer medicine · 2019Article
- Deciphering mechanisms of brain metastasis in melanoma - the gist of the matter.Molecular cancer · 2018Review
- Platelets promoting tumor metastasis: culprits or victims?Journal of thoracic disease · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 2 institutions in 1 country.
Funding
Abstract
Melanoma metastasis to the brain is associated with a poor prognosis. We sought to determine patient demographics and primary tumor factors associated with the development of brain metastasis (BM) and survival. We also investigated whether the BM detection setting (routine screening vs. symptomatic presentation) affected clinical outcomes. A database of melanoma patients seen from 1999 to 2015 at our institution was reviewed to identify patients who developed BM. Patients with BM were matched by initial stage with patients who did not develop BM as a control group. Patient demographics, primary tumor characteristics, and clinical outcomes were analyzed. A total of 123 patients with BM were matched by initial presenting stage to 237 patients without BM. The characteristics of the primary melanoma tumor associated with BM development included location on the scalp (P=0.030), nodular histologic type (P=0.020), and Breslow depth more than 4 mm (P=0.048), whereas location on the leg was associated with decreased BM risk (P=0.006). In patients with BM, time to first recurrence for melanomas of the scalp was significantly shorter (10.8 vs. 24.8 months, P=0.007) than nonscalp head and neck tumors. Patient stage, tumor depth, nodular type, and ulceration were also associated with worse clinical outcomes. There were no differences in the clinical outcomes between patients whose BM were detected upon routine screening versus those detected upon symptomatic presentation. In summary, factors predictive of development of BM included primary scalp location, nodular type, and depth. In BM patients, scalp location, stage, tumor depth, nodular type, and ulceration, but not detection setting, were associated with worse clinical outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.